R3R01 Recruiting Phase 2 Trials for Focal Segmental Glomerulosclerosis (FSGS) / Alport Syndrome Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT05267262Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis